Latest Content

Scientists restored the CCNA2 gene in adult human heart cells, enabling them to divide and form new functional cardiomyocytes—advancing heart repair therapies.

Remibrutinib demonstrated rapid and sustained symptom relief for chronic spontaneous urticaria in a pooled analysis of REMIX-1 and REMIX-2.

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

Improving outcomes in chronic kidney disease relies on improving patient engagement.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Remibrutinib shows rapid and sustained relief for chronic spontaneous urticaria, offering a promising oral treatment option for patients.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

The accelerated approval was based on a study that evaluated the efficacy in unresectable or metastatic nonsquamous NSCLC.